Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT). Vikki Velasquez is a researcher and writer who has managed, coordinated, and ...

Computer science is the study and development of the protocols required for automated processing and manipulation of data. This includes, for example, creating algorithms for efficiently searching ...